📇 Rhumatologue · COMPIEGNE CEDEX · (60) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
6 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
73.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CH CHICN COMPIÈGNE
ZAC DE MERCIÈRE - ZONE 3 8 AV HENRI ADNOT BP 50 029, 60321 COMPIEGNE CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
BMC cancer · 2007
Abstract Background Evaluation of the clinical efficacy and tolerance of metronomic chemotherapy as salvage therapy in a young patient with advanced, platinum resistant, ovarian carcinoma and bad performance status. Case presentation We tried palliative chemotherapy with daily low dose oral cyclophosphamide with a patient suffering from stage IIIC ovarian cancer that responded to daily cyclophosphamide (CTX) after no response to chemotherapy with paclitaxel and carboplatin as first line and progression after second line with topotecan. The progression-free survival time on daily low dose oral cyclophosphamide treatment was 65 months without side effects. She was well during the chemotherapy and lived a normal working and social life. Conclusion We think that use of low dose of oral CTX should be investigated further as a strategy against tumour progression after standard chemotherapy in patients who are platinum resistant with poor performance status.
Journal of cellular physiology · 2019
AbstractData from 423 human epidermal growth factor receptor 2‐negative (HER2−), hormone receptor‐positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane ( p = 0.002) and favorably influenced by early line‐treatment ( p < 0.0001). At 6 months, median progression‐free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
European journal of cancer care · 2019 · Journal Article
De Vincentis G, Frantellizzi V, Follacchio GA, Farcomeni A, et al.
Cancer biology & therapy · 2019 · Journal Article
Gamucci T, Pizzuti L, Natoli C, Mentuccia L, et al.
BMC cancer · 2007 · Case Reports
Samaritani R, Corrado G, Vizza E, Sbiroli C
International journal of cancer · 2020 · Journal Article
Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, et al.
Journal of cellular physiology · 2019 · Journal Article
Pizzuti L, Giordano A, Michelotti A, Mazzotta M, et al.
Journal of cancer research and clinical oncology · 2013 · Journal Article
Natoli C, Vici P, Sperduti I, Grassadonia A, et al.
Computer tomography (CT) scan of advanced ovarian cancer after 65 months after diagnosis showing stable disease without bowel occlusion due to successful colostomy
<b>Copyright information:</b>Taken from "Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer"http://www.biomedcentral.com/1471-2407/7/65BMC Cance
Computer tomography (CT) scan of advanced ovarian cancer before treatment showing conglomeration of the bowel
<b>Copyright information:</b>Taken from "Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer"http://www.biomedcentral.com/1471-2407/7/65BMC Cance
Computer tomography (CT) scan of advanced ovarian cancer before treatment showing conglomeration of the bowel
<b>Copyright information:</b>Taken from "Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer"http://www.biomedcentral.com/1471-2407/7/65BMC Cance
Computer tomography (CT) scan of advanced ovarian cancer after 65 months after diagnosis showing stable disease without bowel occlusion due to successful colostomy
<b>Copyright information:</b>Taken from "Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer"http://www.biomedcentral.com/1471-2407/7/65BMC Cance
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).